Bionet Therapeutics Corp. (7808)

Overview

Bionet Therapeutics Corp. is a biotechnology company specializing in the research, development, and manufacture of advanced cell therapies and regenerative medical products. Founded in 2022 and headquartered in Taipei, the company is dedicated to providing innovative solutions for severe and chronic medical conditions, including acute respiratory distress syndrome, pulmonary fibrosis, chronic kidney failure, diabetic ulcers, degenerative arthritis, and dry eye syndrome.

Employing proprietary cell therapy technologies, Bionet Therapeutics operates a specialized mesenchymal stem cell bank, which caters to both clinical and commercial applications in the field of regenerative medicine. Beyond its clinical pipeline, the company actively engages in contract research, development, and manufacturing organization (CRDMO) services while also creating exosome-based products, ranging from therapeutics to commercialized skin care applications. Bionet Therapeutics Corp. plays a vital role in Taiwan's biopharmaceutical sector by propelling the advancement of cell and gene therapies and enhancing the integration of precision health services in the medical arena.

Products and Services

• Advanced Cell Therapies
  Bionet Therapeutics focuses on innovative cell therapies designed to address critical and chronic health issues. These therapies leverage proprietary technologies to regenerate damaged tissues and improve patient outcomes.
• Regenerative Medical Products
  The company develops cutting-edge medical products aimed at restoring normal biological functions and enhancing healing processes for various chronic conditions.
• Mesenchymal Stem Cell Bank
  Bionet operates a state-of-the-art mesenchymal stem cell bank, ensuring the availability and accessibility of high-quality stem cells for clinical research and therapeutic purposes.
• CRDMO Services
  Providing comprehensive contract research, development, and manufacturing services, Bionet assists other companies in bringing their biotechnological solutions to market efficiently.
• Exosome-based Products
  The company develops and commercializes products that utilize exosomes, including therapeutics aimed at specific diseases and skin care applications that harness the regenerative properties of exosomes.
• Clinical Pipeline
  Bionet is committed to advancing its clinical pipeline with a robust portfolio aimed at addressing unmet medical needs in chronic and severe health conditions.